190
Views
8
CrossRef citations to date
0
Altmetric
ORIGINAL ARTICLE

Paraoxonase and arylesterase activities in patients with papillary thyroid cancer

, , , , &
Pages 259-264 | Received 28 Sep 2014, Accepted 29 Dec 2014, Published online: 27 Feb 2015

References

  • Valko M, Rhodes CJ, Moncol J, Izakovic M, Mazur M. Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem Biol Interact 2006;160:1–40.
  • Valko M, Izakovic M, Mazur M, Rhodes CJ, Telser J. Role of oxygen radicals in DNA damage and cancer incidence. Mol Cell Biochem 2004;266:37–56.
  • Dreher D, Junod AF. Role of oxygen free radicals in cancer development. Eur J Cancer 1996;32:30–8.
  • Girotti AW. Lipid hydroperoxide generation, turnover, and effector action in biological systems. J Lipid Res 1998; 39:1529–42.
  • Miyamoto S, Di Mascio P. Lipid hydroperoxides as a source of singlet molecular oxygen. Subcell Biochem 2014; 77:3–20.
  • Gadomska H, Janecki J, Marianowski L, Nowicka G. Lipids in serum of patients with malignant ovarian neoplasms. Int J Gynaecol Obstet 1997;57:287–93.
  • Ray G, Batra S, Shukla NK, Deo S, Raina V, Ashok S, Husain SA. Lipid peroxidation, free radical production and antioxidant status in breast cancer. Breast Cancer Res Treat 2000;59:163–70.
  • Chander R, Kapoor NK. High density lipoprotein is a scavenger of superoxide anions. See comment in PubMed Commons belowBiochem Pharmacol 1990;40:1663–5.
  • Rajkovic MG, Rumora L, Barisic K. The paraoxonase 1, 2 and 3 in humans. Biochem Med (Zagreb) 2011;21:122–30.
  • Blatter MC, James RW, Messmer S, Barja F, Pometta D. Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein, K-45. Identity of K-45 with paraoxonase. Eur J Biochem 1993;211:871–9.
  • Watson AD, Berliner JA, Hama SY, La Du BN, Faull KF, Fogelman AM, Navab M. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest 1995;96:2882–91.
  • Elkiran ET, Mar N, Aygen B, Gursu F, Karaoglu A, Koca S. Serum paraoxonase and arylesterase activities in patients with lung cancer in a Turkish population. BMC Cancer 2007;7:48.
  • Kodydkova J, Vavrova L, Stankova B, Macasek J, Krechler T, Zak A. Antioxidant status and oxidative stress markers in pancreatic cancer and chronic pancreatitis. Pancreas 2013; 42:614–21.
  • Atay AE, Kaplan MA, Evliyaoglu O, Ekin N, Isikdogan A. The predictive role of Paraoxonase 1 (PON1) activity on survival in patients with metastatic and nonmetastatic gastric cancer. Clin Ter 2014;165:e1–5.
  • Eroglu M, Yilmaz N, Yalcinkaya S, Ay N, Aydin O, Sezer C. Enhanced HDL-cholesterol-associated anti-oxidant PON-1 activity in prostate cancer patients. Kaohsiung J Med Sci 2013;29:368–73.
  • Krzystek-Korpacka M, Boehm D, Matusiewicz M, Diakowska D, Grabowski K, Gamian A. Paraoxonase 1 (PON1) status in gastroesophageal malignancies and associated paraneoplastic syndromes – connection with inflammation. Clin Biochem 2008;41:804–11.
  • Malik UU, Siddiqui IA, Hashim Z, Zarina S. Measurement of serum paraoxonase activity and MDA concentrations in patients suffering with oral squamous cell carcinoma. Clin Chim Acta 2014;430:38–42.
  • Sehitogullari A, Aslan M, Sayir F, Kahraman A, Demir H. Serum paraoxonase-1 enzyme activities and oxidative stress levels in patients with esophageal squamous cell carcinoma. Redox Rep 2014;19:199–205.
  • Schoppy DW, Holsinger FC. Management of the neck in thyroid cancer. Otolaryngol Clin North Am 2014;47: 545–56.
  • Shaha AR. TNM classification of thyroid carcinoma. World J Surg 2007;3:879–87.
  • Eckerson HW, Wyte MC, La Du BN. The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet 1983;35:1126–38.
  • Haagen L, Brock A. A new automated method for phenotyping arylesterase (E.C.3.1.1.2.) based upon inhibition of enzymatic hydrolysis of 4-nitrophenyl acetate by phenyl acetate. Eur J Clin Chem Clin Biochem 1992;30:391–5.
  • Ellman GL. Tissue sulfhydryl groups. Arch Biochem Biophys 1959; 82:70–7.
  • Erel O. A novel automated method to measure total antioxidant response against potent free radical reactions. Clin Biochem 2004;37:112–9.
  • Niki E. Lipid peroxidation: physiological levels and dual biological effects. Free Radic Biol Med 2009;47:469–84.
  • Guyton KZ, Kensler TW. Oxidative mechanisms in carcinogenesis. Br Med Bull 1993;49:523–44.
  • Uchida K. 4-Hydroxy-2-nonenal: a product and mediator of oxidative stress. See comment in PubMed Commons belowProg Lipid Res 2003;42:318–43.
  • Chung FL, Nath RG, Ocando J, Nishikawa A, Zhang L. Deoxyguanosine adducts of t-4-hydroxy-2-nonenal are endogenous DNA lesions in rodents and humans: detection and potential sources. Cancer Res 2000;60:1507–11.
  • Sánchez-Pérez Y, Carrasco-Legleu C, García-Cuellar C, Pérez-Carreón J, Hernández-García S, Salcido-Neyoy M, Alemán-Lazarini L, Villa-Treviño S. Oxidative stress in carcinogenesis. Correlation between lipid peroxidation and induction of preneoplastic lesions in rat hepatocarcinogenesis. Cancer Lett 2005;217:25–32.
  • Young O, Crotty T, O’Connell R, O’Sullivan J, Curran AJ. Levels of oxidative damage and lipid peroxidation in thyroid neoplasia. Head Neck 2010;32:750–6.
  • Lassoued S, Mseddi M, Mnif F, Abid M, Guermazi F, Masmoudi H, El Feki A, Attia H. A comparative study of the oxidative profile in Graves’ disease, Hashimoto's thyroiditis, and papillary thyroid cancer. Biol Trace Elem Res 2010;138:107–15.
  • Yoshida Y, Umeno A, Shichiri M. Lipid peroxidation biomarkers for evaluating oxidative stress and assessing antioxidant capacity in vivo. J Clin Biochem Nutr 2013;52: 9–16.
  • Mackness B, Durrington PN, Mackness MI. Human serum paraoxonase. Gen Pharmacol 1998;31:329–36.
  • Davies HG, Richter RJ, Keifer M, Broomfield CA, Sowalla J, Furlong CE. The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nat Genet 1996;14:334–6.
  • Aviram M, Rosenblat M, Billecke S, Erogul J, Sorenson R, Bisgaier CL, Newton RS, La Du B. Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. See comment in PubMed Commons belowFree Radic Biol Med 1999; 26:892–904.
  • Stevens VL, Rodriguez C, Talbot JT, Pavluck AL, Thun MJ, Calle EE. Paraoxonase 1 (PON1) polymorphisms and prostate cancer in the CPS-II Nutrition Cohort. Prostate 2008;68:1336–40.
  • Deakin SP, Bioletto S, Bochaton-Piallat ML, James RW. HDL-associated paraoxonase-1 can redistribute to cell membranes and influence sensitivity to oxidative stress. Free Radic Biol Med 2011;50:102–9.
  • Deneke SM. Thiol-based antioxidants. Curr Top Cell Regul 2000;36:151–80.
  • Nourazarian AR, Kangari P, Salmaninejad A. Roles of oxidative stress in the development and progression of breast cancer. Asian Pac J Cancer Prev 2014;15:4745–51.
  • Rozenberg O, Rosenblat M, Coleman R, Shih DM, Aviram M. Paraoxonase (PON1) deficiency is associated with increased macrophage oxidative stress: studies in PON1-knockout mice. See comment in PubMed Commons belowFree Radic Biol Med 2003;34:774–84.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.